Funding the future: cell & gene therapy development

Cell & Gene Therapy Insights 2023; 9(3), 295–298

DOI: 10.18609/cgti.2023.046

Published: 28 March 2023
Nick Meyers, Neil Fish

“Moving forward, the traditional funding routes will continue to exist, and we hope there may be more government-led funding available to help companies accelerate their innovations.”

In this viewpoint article, Dr Nick Meyers, Vice President of Product Development, and Dr Neil Fish, Vice President of Business Development at Boyds, discuss the availability of funding for cell and gene therapy product development, and how organizations can differentiate themselves in the market to attract investment.